https://www.biospace.com/depomed-inc-reports-third-quarter-2005-financial-results-55-million-in-license-fees-received
Depomed, Inc. Reports Third Quarter 2005 Financial Results; $55 Million In License Fees Received -...
https://www.ig.com/de/aktien/maerkte-aktien/depomed-inc
Depomed Inc Aktien handeln | Depomed Inc Realtime Aktienkurs | IG Deutschland | IG Deutschland
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio... [DE]
depomedincaktienhandelnrealtime
https://www.biospace.com/santarus-inc-and-depomed-inc-announce-new-u-s-commercialization-agreement-for-glumetza-prescription-products
Santarus Inc. and Depomed, Inc. Announce New U.S. Commercialization Agreement for GLUMETZA...
https://www.ig.com/en-ch/shares/markets-shares/depomed-inc
Trade Depomed Inc Shares | Live Depomed Inc Share Price | IG Switzerland | IG Bank Switzerland
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio... [EN-CH]
live sharetradedepomedincshares
https://www.foxbusiness.com/markets/depomed-rejects-horizon-pharmas-latest-buyout-offer
Depomed rejects Horizon Pharma's latest buyout offer | Fox Business
Depomed Inc's board of directors has rejected Horizon Pharma PLC's latest buyout offer.
horizon pharmadepomedrejectslatestbuyout